@article{outteryck_o_anti-jcv_2012,
title = {Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy},
volume = {259},
issn = {0340-5354},
url = {http://www.ncbi.nlm.nih.gov/pubmed/22527227},
DOI = {10.1007/s00415-012-6487-5},
Language = {English},
Journal = {J. Neurol.},
author = {{Outteryck O} and {Ongagna JC} and {Duhamel A} and {Zephir H} and {Collongues N} and {Lacour A} and {Fleury MC} and {Berteloot AS} and {Blanc F} and {Giroux M} and {Vermersch P} and {de Seze J}},
year = {2012},
keywords = {Adolescent, Adult, Aged, Antibodies, Monoclonal, Humanized/administration & dosage, Antibodies, Monoclonal, Humanized/adverse effects*, Antibodies, Viral/biosynthesis*, Cohort Studies, Female, France/epidemiology, Humans, JC Virus/immunology*, Leukoencephalopathy, Progressive Multifocal/epidemiology*, Leukoencephalopathy, Progressive Multifocal/immunology, Leukoencephalopathy, Progressive Multifocal/virology, Male, Middle Aged, Multiple Sclerosis/drug therapy, Multiple Sclerosis/epidemiology*, Multiple Sclerosis/immunology*, Natalizumab, Prevalence, Young Adult},
pages = {2293-2298}
}

{"_id":"sLNgyuhpaeTgMGkWL","bibbaseid":"outterycko-ongagnajc-duhamela-zephirh-collonguesn-lacoura-fleurymc-bertelootas-etal-antijcvantibodyprevalenceinafrenchcohortofmspatientsundernatalizumabtherapy-2012","authorIDs":[],"author_short":["Outteryck O","Ongagna JC","Duhamel A","Zephir H","Collongues N","Lacour A","Fleury MC","Berteloot AS","Blanc F","Giroux M","Vermersch P","de Seze J"],"bibdata":{"bibtype":"article","type":"article","title":"Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy","volume":"259","issn":"0340-5354","url":"http://www.ncbi.nlm.nih.gov/pubmed/22527227","doi":"10.1007/s00415-012-6487-5","language":"English","journal":"J. Neurol.","author":[{"firstnames":[],"propositions":[],"lastnames":["Outteryck O"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Ongagna JC"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Duhamel A"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Zephir H"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Collongues N"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Lacour A"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Fleury MC"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Berteloot AS"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Blanc F"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Giroux M"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Vermersch P"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["de Seze J"],"suffixes":[]}],"year":"2012","keywords":"Adolescent, Adult, Aged, Antibodies, Monoclonal, Humanized/administration & dosage, Antibodies, Monoclonal, Humanized/adverse effects*, Antibodies, Viral/biosynthesis*, Cohort Studies, Female, France/epidemiology, Humans, JC Virus/immunology*, Leukoencephalopathy, Progressive Multifocal/epidemiology*, Leukoencephalopathy, Progressive Multifocal/immunology, Leukoencephalopathy, Progressive Multifocal/virology, Male, Middle Aged, Multiple Sclerosis/drug therapy, Multiple Sclerosis/epidemiology*, Multiple Sclerosis/immunology*, Natalizumab, Prevalence, Young Adult","pages":"2293-2298","bibtex":"@article{outteryck_o_anti-jcv_2012,\r\ntitle = {Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy},\r\nvolume = {259},\r\nissn = {0340-5354},\r\nurl = {http://www.ncbi.nlm.nih.gov/pubmed/22527227},\r\nDOI = {10.1007/s00415-012-6487-5},\r\nLanguage = {English},\r\nJournal = {J. Neurol.},\r\nauthor = {{Outteryck O} and {Ongagna JC} and {Duhamel A} and {Zephir H} and {Collongues N} and {Lacour A} and {Fleury MC} and {Berteloot AS} and {Blanc F} and {Giroux M} and {Vermersch P} and {de Seze J}},\r\nyear = {2012},\r\nkeywords = {Adolescent, Adult, Aged, Antibodies, Monoclonal, Humanized/administration & dosage, Antibodies, Monoclonal, Humanized/adverse effects*, Antibodies, Viral/biosynthesis*, Cohort Studies, Female, France/epidemiology, Humans, JC Virus/immunology*, Leukoencephalopathy, Progressive Multifocal/epidemiology*, Leukoencephalopathy, Progressive Multifocal/immunology, Leukoencephalopathy, Progressive Multifocal/virology, Male, Middle Aged, Multiple Sclerosis/drug therapy, Multiple Sclerosis/epidemiology*, Multiple Sclerosis/immunology*, Natalizumab, Prevalence, Young Adult},\r\npages = {2293-2298}\r\n}\r\n\r\n","author_short":["Outteryck O","Ongagna JC","Duhamel A","Zephir H","Collongues N","Lacour A","Fleury MC","Berteloot AS","Blanc F","Giroux M","Vermersch P","de Seze J"],"key":"outteryck_o_anti-jcv_2012","id":"outteryck_o_anti-jcv_2012","bibbaseid":"outterycko-ongagnajc-duhamela-zephirh-collonguesn-lacoura-fleurymc-bertelootas-etal-antijcvantibodyprevalenceinafrenchcohortofmspatientsundernatalizumabtherapy-2012","role":"author","urls":{"Paper":"http://www.ncbi.nlm.nih.gov/pubmed/22527227"},"keyword":["Adolescent","Adult","Aged","Antibodies","Monoclonal","Humanized/administration & dosage","Antibodies","Monoclonal","Humanized/adverse effects*","Antibodies","Viral/biosynthesis*","Cohort Studies","Female","France/epidemiology","Humans","JC Virus/immunology*","Leukoencephalopathy","Progressive Multifocal/epidemiology*","Leukoencephalopathy","Progressive Multifocal/immunology","Leukoencephalopathy","Progressive Multifocal/virology","Male","Middle Aged","Multiple Sclerosis/drug therapy","Multiple Sclerosis/epidemiology*","Multiple Sclerosis/immunology*","Natalizumab","Prevalence","Young Adult"],"downloads":0},"bibtype":"article","biburl":"https://pro.univ-lille.fr/fileadmin/user_upload/pages_pros/patrick_devos/duhamel.bib","creationDate":"2019-06-21T09:30:55.110Z","downloads":0,"keywords":["adolescent","adult","aged","antibodies","monoclonal","humanized/administration & dosage","antibodies","monoclonal","humanized/adverse effects*","antibodies","viral/biosynthesis*","cohort studies","female","france/epidemiology","humans","jc virus/immunology*","leukoencephalopathy","progressive multifocal/epidemiology*","leukoencephalopathy","progressive multifocal/immunology","leukoencephalopathy","progressive multifocal/virology","male","middle aged","multiple sclerosis/drug therapy","multiple sclerosis/epidemiology*","multiple sclerosis/immunology*","natalizumab","prevalence","young adult"],"search_terms":["anti","jcv","antibody","prevalence","french","cohort","patients","under","natalizumab","therapy","outteryck o","ongagna jc","duhamel a","zephir h","collongues n","lacour a","fleury mc","berteloot as","blanc f","giroux m","vermersch p","de seze j"],"title":"Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy","year":2012,"dataSources":["Tt6zYqvN5kE3wbwiR"]}